Nat Commun:揭示淋巴结中重要信号通路,以更好理解病理生理过程

2020-02-11 不详 生物探索

SARS、MERS以及最近的新型冠状病毒2019-nCoV等病原体已成为全球性威胁。淋巴结(LN)通过为免疫细胞的生长提供庇护所并抵抗病原体,从而与传染病作斗争。但是,人们对LN的特定内部运作方式知之甚少。韩国基础科学研究所(IBS)的科学家们发现Hippo-YAP/TAZ信号通路在LN的形成和维持中起主要作用。该研究报告发表在《Nature Communications》杂志上。

SARS、MERS以及最近的新型冠状病毒2019-nCoV等病原体已成为全球性威胁。淋巴结(LN)通过为免疫细胞的生长提供庇护所并抵抗病原体,从而与传染病作斗争。但是,人们对LN的特定内部运作方式知之甚少。韩国基础科学研究所(IBS)的科学家们发现Hippo-YAP/TAZ信号通路在LN的形成和维持中起主要作用。该研究报告发表在《Nature Communications》杂志上。


https://doi.org/10.1038/s41467-020-14293-1

LN的关键成分之一是成纤维网状细胞(FRC),它形成LN的基础结构,并通过释放细胞因子(一种对免疫很重要的蛋白)来触发免疫反应。在LN的发展过程中,功能性FRC形成:一个不明确的间充质细胞群分化为FRC前体,然后进一步发展为具有免疫功能的成熟FRC。


在淋巴结的生长和维持过程中,YAP / TAZ活性和p52 / RelB活性协调的重要性

该研究小组证实了Hippo途径(一种细胞增殖和器官大小控制的关键调节剂)在FRC成熟过程中的重要性,他们使用了20多种不同的转基因小鼠模型来表征特定时间点的Hippo途径,从而在FRC发展的各个阶段消耗了YAP / TAZ蛋白,通过仔细检查小鼠的LN发现,当FRC前体中的YAP / TAZ降低时,FRC会转变为脂肪细胞。从机理上讲,YAP / TAZ应该与调节FRC的关键成分结合,例如p52,二者之间的相互作用促进了趋化因子表达。


YAP/TAZ耗尽会将FRC前体转化为脂肪细胞

这一发现将YAP / TAZ视为FRC成熟的关键调节剂,有望更好地了解FRC介导的病理生理过程。在未来的研究中,将集中于确定影响全身免疫反应的疾病或状况是否可以与FRCs中Hippo信号通路的改变有关,以及调节FRC中Hippo信号传导是否可以作为可行的治疗选择。除了在针对流感的免疫反应中的重要性外,FRC还因其在癌症进展和患者预后中的作用而获得广泛认可。

原始出处:

Sung Yong Choi, Hosung Bae, Sun-Hye Jeong, et.al. YAP/TAZ direct commitment and maturation of lymph node fibroblastic reticular cells. Nature Communications 24 January 2020

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2087656, encodeId=5112208e656ed, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Mar 11 16:51:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884112, encodeId=958a1884112cd, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Dec 11 11:51:00 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701783, encodeId=953e1e01783e8, content=<a href='/topic/show?id=9c35e104573' target=_blank style='color:#2F92EE;'>#病理生理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71045, encryptionId=9c35e104573, topicName=病理生理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d59730392519, createdName=许安, createdTime=Tue Sep 01 04:51:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293087, encodeId=87ae129308e09, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Wed Feb 12 23:51:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539762, encodeId=ce401539e6264, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Wed Feb 12 23:51:00 CST 2020, time=2020-02-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2087656, encodeId=5112208e656ed, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Mar 11 16:51:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884112, encodeId=958a1884112cd, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Dec 11 11:51:00 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701783, encodeId=953e1e01783e8, content=<a href='/topic/show?id=9c35e104573' target=_blank style='color:#2F92EE;'>#病理生理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71045, encryptionId=9c35e104573, topicName=病理生理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d59730392519, createdName=许安, createdTime=Tue Sep 01 04:51:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293087, encodeId=87ae129308e09, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Wed Feb 12 23:51:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539762, encodeId=ce401539e6264, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Wed Feb 12 23:51:00 CST 2020, time=2020-02-12, status=1, ipAttribution=)]
    2020-12-11 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=2087656, encodeId=5112208e656ed, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Mar 11 16:51:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884112, encodeId=958a1884112cd, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Dec 11 11:51:00 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701783, encodeId=953e1e01783e8, content=<a href='/topic/show?id=9c35e104573' target=_blank style='color:#2F92EE;'>#病理生理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71045, encryptionId=9c35e104573, topicName=病理生理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d59730392519, createdName=许安, createdTime=Tue Sep 01 04:51:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293087, encodeId=87ae129308e09, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Wed Feb 12 23:51:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539762, encodeId=ce401539e6264, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Wed Feb 12 23:51:00 CST 2020, time=2020-02-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2087656, encodeId=5112208e656ed, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Mar 11 16:51:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884112, encodeId=958a1884112cd, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Dec 11 11:51:00 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701783, encodeId=953e1e01783e8, content=<a href='/topic/show?id=9c35e104573' target=_blank style='color:#2F92EE;'>#病理生理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71045, encryptionId=9c35e104573, topicName=病理生理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d59730392519, createdName=许安, createdTime=Tue Sep 01 04:51:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293087, encodeId=87ae129308e09, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Wed Feb 12 23:51:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539762, encodeId=ce401539e6264, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Wed Feb 12 23:51:00 CST 2020, time=2020-02-12, status=1, ipAttribution=)]
    2020-02-12 sodoo
  5. [GetPortalCommentsPageByObjectIdResponse(id=2087656, encodeId=5112208e656ed, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Mar 11 16:51:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884112, encodeId=958a1884112cd, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Dec 11 11:51:00 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701783, encodeId=953e1e01783e8, content=<a href='/topic/show?id=9c35e104573' target=_blank style='color:#2F92EE;'>#病理生理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71045, encryptionId=9c35e104573, topicName=病理生理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d59730392519, createdName=许安, createdTime=Tue Sep 01 04:51:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293087, encodeId=87ae129308e09, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Wed Feb 12 23:51:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539762, encodeId=ce401539e6264, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Wed Feb 12 23:51:00 CST 2020, time=2020-02-12, status=1, ipAttribution=)]

相关资讯

JAMA Surg:为获得小肠神经内分泌瘤准确分期至少需切除8个淋巴结

研究认为,小肠神经内分泌肿瘤根治性切除的患者,为获得准确的淋巴结分期至少需要8个淋巴结,存在4个以上淋巴结阳性人群的3年预后变差,彻底的区域淋巴结切除是准确分期和治疗疾病的关键

Nat Med:曹雪涛团队发现乳腺癌患者易发淋巴结转移新机制

肿瘤原发灶能够诱导远端转移器官中基质和相关免疫细胞成分与功能变化,形成一个利于肿瘤细胞定居生长“土壤”的 “肿瘤转移前微环境”。

Ann Thorac Surg:胸导管旁淋巴结--新概念?

胸导管切除是常规en bloc纵隔食管癌切除的一部分。随着微创技术的适应,很多中心开始原位保留胸导管。然而,前期的研究表明该区域存在胸导管淋巴结,并可出现转移。

右侧鼻腔淋巴结外NK/T细胞性淋巴瘤(鼻型)CT病例!

女性,鼻塞1年余,左侧进行性鼻、面部肿胀2月,反复发热10日。

Prostate Cancer P D:[68Ga] Ga-PSMA 11 PET在淋巴结中检测前列腺癌的表现研究

生化复发(BCR)前列腺癌(PCa)患者的节点复发挽救性淋巴结清扫(sLND)在当前的指南中仍旧不推荐,主要是由于当前传统成像的不准确性造成。最近,研究人员评估了[68Ga] Ga-PSMA 11 PET(PSMA-PET)在检测PCa淋巴结转移中的表现,并通过sLND进行了病理学确认。研究人员对MEDLINE、SCOPUS、Web of Science和Cochrane Library进行了搜索

Cancer Res:阴险!复旦科学家发现肿瘤能将杀伤性T细胞囚禁在淋巴结中,让调节T细胞成为“猪队友”

最近,复旦大学王宾教授领导的团队又发现,肿瘤将T细胞囚禁在了淋巴结中,使他们不能出去抗癌。不过,与上次不同的是,这次研究者们终于弄清了肿瘤的阴谋是如何得逞的,并且,他们还找到了解救T细胞的办法!